Towards a Functional Cure for Hepatitis B Virus: A 2022 Update on New Antiviral Strategies

• Published in: Viruses Vol. 14; no. 11; p. 2404
• Main Authors: Degasperi, Elisabetta, Anolli, Maria Paola, Lampertico, Pietro
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 29.10.2022; MDPI
• Subjects: Antigens; Antiviral agents; Antiviral Agents - pharmacology; Antiviral Agents - therapeutic use; Antiviral drugs; Care and treatment; Chronic infection; Cirrhosis; clinical trials; DNA, Viral; Drug development; Drug dosages; Fibrosis; functional cure; Genetic aspects; Genomes; HBV; Hepatitis B; Hepatitis B - drug therapy; Hepatitis B Antibodies; Hepatitis B surface antigen; Hepatitis B Surface Antigens; Hepatitis B virus - genetics; Hepatitis B, Chronic - drug therapy; Humans; Immunomodulation; investigational drugs; Liver cancer; Liver cirrhosis; Liver diseases; nucleos(t)ide analogues; Physiological aspects; Polypeptides; Proteins; Review; Seroconversion; Signal transduction; Virus Replication; Italy; functional cure; clinical trials; HBV; investigational drugs; nucleos(t)ide analogues

Chronic infection with hepatitis B virus (HBV) represents one of the main causes of the development of cirrhosis and its complications. Treatment with potent third-generation nucleos(t)ide analogues (NUCs) results in >99% HBV DNA undetectability, and prevents fibrosis progression and liver-relate...